ValuEngine upgraded shares of Transgenomic (NASDAQ:PRPO) from a strong sell rating to a sell rating in a research report report published on Friday morning.

Shares of Transgenomic (NASDAQ PRPO) traded down $0.01 on Friday, hitting $1.29. The stock had a trading volume of 22,359 shares, compared to its average volume of 58,755. Transgenomic has a 1 year low of $1.18 and a 1 year high of $47.70. The company has a current ratio of 0.08, a quick ratio of 0.07 and a debt-to-equity ratio of 0.01.

TRADEMARK VIOLATION WARNING: “Transgenomic (PRPO) Upgraded to Sell by ValuEngine” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/02/transgenomic-prpo-upgraded-to-sell-by-valuengine.html.

Transgenomic Company Profile

Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.

Receive News & Stock Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related stocks with our FREE daily email newsletter.